Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Soluble CD40 ligand, high sensitive C-reactive protein and fetuin-A levels in patients with essential thrombocythemia.

Authors: Bilgir, F  Bilgir, O  Kebapcilar, L  Calan, M  Ozdemirkiran, F  Cinali, T  Bozkaya, G 
Citation: Bilgir F, etal., Transfus Apher Sci. 2012 Feb;46(1):67-71. doi: 10.1016/j.transci.2011.11.013. Epub 2011 Dec 23.
Pubmed: (View Article at PubMed) PMID:22196954
DOI: Full-text: DOI:10.1016/j.transci.2011.11.013

BACKGROUND: CD40 ligand (CD40L) is expressed on the surface of activated platelets and activated T lymphocytes. Circulating soluble CD40 ligand (sCD40L) is formed from these molecules proteolytically. Fetuin-A is a potent antiinflammatory cytokine. AIM OF THE STUDY: In this study, we aim to investigate sCD40L levels to determine whether there is platelet activation and to measure high sensitive C-reactive protein (hs-CRP) levels to demonstrate if this leads to an inflammatory process and also to study fetuin-A levels to see if there is any concomitant antiinflammatory event in patients with essential thrombocythemia (ET). METHODS: We compared 30 patients with essential thrombocythemia with 30 control subjects and in these patients we measured levels of sCD40L, hs-CRP and fetuin-A. RESULTS: sCD40L levels were significantly higher in the ET group compared to the control group (30.6+/-14.4 vs. 18.5+/-8.9, p=0.001). Although fetuin-A levels showed a slight trend to be increased in ET patients, the difference did not reach significance (4.5+/-4.2 vs. 3.2+/-2.1, p=0.158). There were no statistically significant differences in hs-CRP levels (24.6+/-4.9 vs. 25.0+/-5.2, p=0.750). CONCLUSION: sCD40L was significantly higher in patients with an ET without any association with an inflammatory process and we believe this may be a marker of platelet regeneration.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11344979
Created: 2016-07-11
Species: All species
Last Modified: 2016-07-11
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.